Minoguchi K, Adachi M
First Department of Internal Medicine, Showa University School of Medicine.
Nihon Rinsho. 2001 Oct;59(10):1979-85.
Cysteinyl leukotriene (CysLT) C4, D4, and E4 play key roles in asthma. CysLTs are newly generated after cellular activation and are produced by eosinophils, mast cells, alveolar macrophages, and neutrophils. Pharmacological actions of CysLTs include potent bronchoconstriction, increased microvascular leakage and mucus secretion, chemoattraction of eosinophils, acceleration of eosinophil apoptosis, and proliferation of human airway smooth muscle. Recent studies demonstrated that CysLT1 receptors are distributed on CD34+ stem cells, eosinophils, monocytes, macrophages, basophils, and B cells in addition to airway smooth muscle. Because of these wide variety of distribution, Cys LTs may have another important roles in airway inflammation. CysLT1 receptor antagonist is widely used and found to be beneficial for the chronic management of asthma especially to symptomatic patients who had already been treated with moderate to high doses of inhaled corticosteroids and also to mild to moderate steroid-naive asthmatic patients.
半胱氨酰白三烯（CysLT）C4、D4和E4在哮喘中起关键作用。CysLTs在细胞活化后新生成，由嗜酸性粒细胞、肥大细胞、肺泡巨噬细胞和中性粒细胞产生。CysLTs的药理作用包括强效支气管收缩、微血管渗漏增加和黏液分泌、嗜酸性粒细胞趋化、嗜酸性粒细胞凋亡加速以及人气道平滑肌增殖。最近的研究表明，除气道平滑肌外，CysLT1受体还分布于CD34+干细胞、嗜酸性粒细胞、单核细胞、巨噬细胞、嗜碱性粒细胞和B细胞上。由于分布广泛，CysLTs可能在气道炎症中发挥其他重要作用。CysLT1受体拮抗剂被广泛使用，并且发现对哮喘的慢性管理有益，特别是对已经接受中度至大剂量吸入性糖皮质激素治疗的有症状患者以及轻度至中度未使用过糖皮质激素的哮喘患者。
